Company intelligence / Profile preview
AtheroNova Inc.
Irvine, California, United Statesatheronova.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
AtheroNova's lead compound AHRO-001 completed Phase Ib safety trials in Russia with no significant adverse effects reported. The program aimed to demonstrate regression of atherosclerotic plaque using bile-acid based therapy. Further development was halted after the company filed for bankruptcy protection in March 2015[3][6].
- Therapeutic areas
- Men's HealthCardiovascularNeurology
- Modalities
- Small molecules (bile acid-based compounds)Natural compounds
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
'OOO CardioNova' (Russian subsidiary of Maxwell Biotech Group)
Beyond the preview
Go deeper on AtheroNova Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AtheroNova Inc..